Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 1/2 3Phase 2 2Phase 1 2Phase 4 1

Status

Completed 2Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Carcinoma, Medullary 4Lung Neoplasms 2Thyroid Neoplasms 1Neoplasm Metastasis 1Familial medullary thyroid carcinoma 1Differentiated Thyroid Cancer 1Carcinoma, Squamous Cell 1Carcinoma, Large Cell 1Adenocarcinoma 1

Interventions

vandetanib 4cabozantinib 2selpercatinib 1pralsetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Medullary × vandetanib × Clear all
NCT01298323 2026-04-17

Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment

Sanofi

Phase 3 Completed
205 enrolled 10 charts

Neoplasm Metastasis, Carcinoma, Medullary

NCT04211337 2026-03-19

LIBRETTO-531

Eli Lilly and Company

Phase 3 Active not recruiting
291 enrolled 16 charts 1 FDA

Carcinoma, Medullary

NCT00410761 2025-09-24

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Sanofi

Phase 3 Completed
331 enrolled 15 charts
EndocrineHead & Neck

Familial medullary thyroid carcinoma, Thyroid Neoplasms, Carcinoma, Medullary

NCT04760288 2024-01-05

AcceleRET-MTC

Hoffmann-La Roche

Phase 3 Withdrawn

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡